A fingernail scan could reveal hidden diabetes risk

NCT ID NCT06261944

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are testing a device called Glyconics-DS that shines near-infrared light on a fingernail to measure glycated keratin, a marker linked to blood sugar. The trial enrolls about 486 adults who do not know their diabetes status and compares the scan result with a standard HbA1c blood test. The goal is to see whether the fingernail scan can correctly sort people into lower or higher diabetes risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
near-infrared scan of glycated keratin in a fingernail
What this could lead to
If it works, people could learn their diabetes risk from a quick fingernail scan instead of a blood draw, which may make screening easier to offer in more places.
What could go wrong
The scan may not match the blood test closely enough to be trusted, especially for people with nail damage or other conditions. This is a device accuracy study, so it cannot show whether screening this way improves health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

486 people

The number who actually took part.

Started

Mar 2024

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Apparently healthy adults (≥18 years of age) with unknown diabetes status willing to participate in and provide a written consent for the study * Willingness to undertake assisted assessment of glycaemia: by both the NIR spectral measurements in a chosen middle fingernail, and HbA1c (blood sample) * Individuals with at least one visually assessed undamaged, intact (preferably middle) fingernail. Exclusion Criteria: * Individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as: * Severe forms of anaemia (diagnosed iron deficiency, sickle cell anaemia or similar). * Haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular (local) laboratory assays for HbA1c. * Severe renal impairment (CKD stage III-IV) or decompensated hepatic disease. * Severe Vitamin D deficiency (diagnosed or measured 25(OH)D3 \< 25 nmol/ml). * Known severe immunodeficiency such as HIV, malignancy or other chronic condition significantly impacting assessment of glycaemia. * Eating disorders (as per clinical assessment) * Recent (within 28 days) blood donation * Any other type of known diabetes than T2DM, if diagnosed (T1DM, GDM, MODY, etc.) * Any structural, deviating and visually detectable deviations in the appearance of the (only/ to be assessed) middle fingernail potentially impacting the spectra measurement, including: * nail dystrophy or deformity * severe nail infections (onychomycosis causing visual changes in the appearance of the nail). * rare hereditable conditions impacting the structure of keratin. * mechanical damage or marks on the surface of the nail after removal of nail polish. * use of acrylic or gel nail decoration and polish, which cannot be removed with acetone (use of acetone necessitates a 15 min post-removal wash-out time) * Any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of HbA1c value.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sant Pau Hospital

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.